International Clinical Psychopharmacology最新文献_第6页

Managing depression in the elderly: real-world clinical considerations and perspectives. 老年人抑郁症的管理：现实世界的临床考虑和观点。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2025-11-01 Epub Date: 2025-01-09 DOI: 10.1097/YIC.0000000000000577

Siegfried Kasper, Raffaele Antonelli Incalzi, Marco Bozzali, Pedro Morgado, Marcin Siwek

{"title":"Managing depression in the elderly: real-world clinical considerations and perspectives.","authors":"Siegfried Kasper, Raffaele Antonelli Incalzi, Marco Bozzali, Pedro Morgado, Marcin Siwek","doi":"10.1097/YIC.0000000000000577","DOIUrl":"10.1097/YIC.0000000000000577","url":null,"abstract":"This study aims to elucidate current trends in clinical practice for managing depression in elderly patients, focusing on the utilization of pharmacotherapeutics and integrated care models to improve patient outcomes. A comprehensive survey was conducted among physicians from various European countries to gather insights into prescribing habits, treatment patterns, and the impact of comorbidities on therapeutic choices, with a focus on trazodone. The participants included psychiatrists, general practitioners, and neurologists actively involved in elderly depression care. The findings reveal a preference among physicians for using antidepressants like trazodone, due to efficacy and tolerability. Selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors were also commonly prescribed, while tricyclic antidepressants and monoamine oxidase inhibitors were less favored. Psychiatric conditions and sleep disturbances significantly influenced treatment decisions. The survey underscored the importance of multidisciplinary management and the crucial role of caregivers in the treatment process. Effective management of depression in the elderly demands a precision approach that incorporates a thorough understanding of pharmacology, comorbidities, and a collaborative approach to maximize the effects of treatment while trying to minimize polypharmacy and the co-occurring side effects. The study highlights the need for tailored treatment strategies that address the complex needs of the elderly to enhance their quality of life and treatment outcomes.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"339-352"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12459149/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Selective serotonin reuptake inhibitors and quality of life: a meta-analysis of randomized placebo-controlled trials. 选择性血清素再摄取抑制剂和生活质量：随机安慰剂对照试验的荟萃分析。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2025-11-01 Epub Date: 2025-02-28 DOI: 10.1097/YIC.0000000000000585

Dimy Fluyau, Vasanth Kattalai Kailasam, Paul Kim, Neelambika Revadigar

{"title":"Selective serotonin reuptake inhibitors and quality of life: a meta-analysis of randomized placebo-controlled trials.","authors":"Dimy Fluyau, Vasanth Kattalai Kailasam, Paul Kim, Neelambika Revadigar","doi":"10.1097/YIC.0000000000000585","DOIUrl":"10.1097/YIC.0000000000000585","url":null,"abstract":"The benefit of selective serotonin reuptake inhibitors (SSRIs) in improving quality of life (QoL) has been investigated in randomized-controlled trials (RCTs) with equivocal results. This study explored whether SSRIs could improve QoL in individuals with medical, psychiatric, and neuropsychiatric conditions. RCTs were searched in PubMed, Embase, Scopus, Ovid, and Google Scholar. Data were synthesized via a meta-analysis. Subgroup and meta-regression analyses were performed. The sample size was 9,070. Compared with placebo, SSRIs showed statistically significant improvements in QoL in cancer ( d = 0.30), major depressive disorder ( d = 0.27), premenstrual dysphoric disorder ( d = 0.38), type 2 diabetes mellitus ( d = 0.48), persistent depressive disorder ( d = 0.32), and menopausal symptoms ( d = 0.40). Paroxetine exhibited the highest effect size. No significant improvements were noted in chronic obstructive pulmonary disease ( d = 0.65, P = 0.09), congestive heart failure ( d = 0.46, P = 0.27), and irritable bowel syndrome ( d = 0.26, P = 0.127). The reduction in depressive symptoms improved QoL. Small-study effects, high attrition rates, and demographic imbalances are limiting factors to recommend SSRIs to improve QoL. Future research should focus on QoL domains and pharmacological properties of each SSRI.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"321-332"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Resistance to antidepressant treatment among patients with major depressive disorder: a nationwide study. 重度抑郁症患者对抗抑郁治疗的抵触情绪：一项全国性研究。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2025-11-01 Epub Date: 2024-12-23 DOI: 10.1097/YIC.0000000000000574

Li-Chi Chen, Mu-Hong Chen, Ya-Mei Bai, Tzeng-Ji Chen, Tung-Ping Su

{"title":"Resistance to antidepressant treatment among patients with major depressive disorder: a nationwide study.","authors":"Li-Chi Chen, Mu-Hong Chen, Ya-Mei Bai, Tzeng-Ji Chen, Tung-Ping Su","doi":"10.1097/YIC.0000000000000574","DOIUrl":"10.1097/YIC.0000000000000574","url":null,"abstract":"Treatment-resistant depression (TRD) has great clinical importance because it has the highest disability burden of all depressive conditions. We investigated the prevalence of TRD and identified the risk and protective factors associated with antidepressant resistance among adult patients with major depressive disorder (MDD). A total of 176 132 adult patients with MDD were selected from the Taiwan National Health Insurance Research Database between 2001 and 2010 and followed for 1 year. TRD was defined as nonresponse to at least two antidepressants, and treatment-resistant tendency was defined as nonresponse to at least the first antidepressant. General physical condition measured by the Charlson Comorbidity Index (CCI), psychiatric comorbidities, and economic status were assessed. Only 2.6% ( n = 4608) of the adults with MDD met the TRD criteria, but 26.4% ( n = 46 491) were classified as having treatment-resistant tendency. The following psychiatric comorbidities were related to TRD: anxiety disorders [odds ratio (OR): 1.88], substance use disorders (OR: 1.73), alcohol use disorders (OR: 1.27), and personality disorders (OR: 2.12). In addition, a more severe physical condition (higher CCI) increased the likelihood of TRD (OR: 1.12). Psychiatric comorbidities and poor general physical condition may increase the likelihood of antidepressant treatment failure.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"333-338"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment options for depression in Parkinson's disease: a mini-review. 帕金森病抑郁症的治疗选择：一个小型回顾。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2025-11-01 Epub Date: 2025-03-13 DOI: 10.1097/YIC.0000000000000588

Alberto Raggi, Alessandro Serretti, Raffaele Ferri

{"title":"Treatment options for depression in Parkinson's disease: a mini-review.","authors":"Alberto Raggi, Alessandro Serretti, Raffaele Ferri","doi":"10.1097/YIC.0000000000000588","DOIUrl":"10.1097/YIC.0000000000000588","url":null,"abstract":"Depression is a common comorbidity in Parkinson's disease (PD), significantly reducing patients' quality of life. This mini-review examines pharmacological and nonpharmacological therapies for managing depression in PD, analyzing their benefits, and limitations. Pharmacological options include tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), levodopa, dopaminergic agonists, and monoamine oxidase B inhibitors. Nonpharmacological strategies involve brief psychodynamic therapy, cognitive-behavioral therapy (CBT), physical exercise, phytomedicine, massage therapy, music therapy, phototherapy, yoga, repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation, electroconvulsive therapy (ECT), and deep brain stimulation. SSRIs, SNRIs, and some dopamine agonists have shown effectiveness and good tolerability, especially when combined with CBT or rTMS. For severe or refractory cases, ECT remains a viable option. Although many of these therapies show promise, the limited number and scale of studies for each treatment restrict the strength of current evidence. Further large-scale, multicenter randomized-controlled trials are essential to validate these preliminary findings and establish evidence-based guidelines. In addition, the potential benefits of social support and brief psychodynamic therapy in the context of PD-related depression require further exploration to provide holistic care strategies for this population.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"312-320"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Agranulocytosis after long-term clozapine use: a case report. 长期使用氯氮平后粒细胞缺乏症1例。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2025-11-01 Epub Date: 2025-09-23 DOI: 10.1097/YIC.0000000000000594

Agostina Secchi, Madelaine Bridges, Eromona Whiskey, Sukhi Shergill

引用次数: 0

Brexpiprazole augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary retrospective observational study. 布瑞吡拉唑增强治疗难治性强迫症：一项初步回顾性观察研究。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2025-11-01 Epub Date: 2025-02-06 DOI: 10.1097/YIC.0000000000000583

Luca Giacovelli, Eleonora Piccoli, Paola Landi, Matteo Vismara, Beatrice Benatti, Bernardo Dell'Osso

{"title":"Brexpiprazole augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary retrospective observational study.","authors":"Luca Giacovelli, Eleonora Piccoli, Paola Landi, Matteo Vismara, Beatrice Benatti, Bernardo Dell'Osso","doi":"10.1097/YIC.0000000000000583","DOIUrl":"10.1097/YIC.0000000000000583","url":null,"abstract":"Obsessive-compulsive disorder (OCD) is a chronic illness associated with significant functional impairment. Monotherapy with serotonin reuptake inhibitors (SRIs) often leads to only partial improvement of symptoms. In such cases, a common, well established, treatment approach for most patients is the augmentation of SRI therapy with antipsychotic medications. Brexpiprazole is an atypical antipsychotic agent that acts as a partial agonist of 5-HT1A, D2, and D3 receptors. Purpose of this retrospective observational study was to evaluate the effectiveness and tolerability of brexpiprazole as augmentation to SRIs in patients with treatment-resistant OCD. This preliminary study included a sample of 10 patients diagnosed with treatment-resistant OCD who underwent a 12-week trial of augmentative brexpiprazole, starting at a dose of 1 mg/day, with dosage adjustments based on clinical judgment. Treatment response was assessed through changes in the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score from baseline to the end of the 12-week observation period. Adverse events were systematically recorded. Significant improvement was observed after the 12-week period: at the endpoint, seven patients (70%) achieved a ≥25% reduction in Y-BOCS total score compared to baseline, with five of them (50% of the overall sample) showing a more robust clinical response (≥35% reduction). Mild adverse effects, such as sedation and weight gain, were reported by two participants (20% of the overall sample). These findings suggest that brexpiprazole may offer a promising effectiveness and tolerability profile in the management of treatment-resistant OCD.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"e14-e20"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12459139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Underinvestigated aspects of depression treatment: comorbidity, quality-of-life, and novel adjuncts. 抑郁症治疗未被充分研究的方面：合并症、生活质量和新的辅助因素。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2025-11-01 Epub Date: 2025-09-23 DOI: 10.1097/YIC.0000000000000606

Alessandro Serretti

引用次数: 0

Intravenous trazodone for the treatment of psychomotor agitation and associated symptoms in major depressive disorder patients experiencing a depressive episode with mixed features. 静脉曲唑酮治疗伴有混合特征的抑郁发作的重度抑郁症患者的精神运动性躁动及相关症状

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2025-11-01 Epub Date: 2025-01-13 DOI: 10.1097/YIC.0000000000000580

Pietro Carmellini, Alessandro Cuomo, Caterina Pierini, Simone Pardossi, Mario Pinzi, Elisa Mariantoni, Andrea Fagiolini

{"title":"Intravenous trazodone for the treatment of psychomotor agitation and associated symptoms in major depressive disorder patients experiencing a depressive episode with mixed features.","authors":"Pietro Carmellini, Alessandro Cuomo, Caterina Pierini, Simone Pardossi, Mario Pinzi, Elisa Mariantoni, Andrea Fagiolini","doi":"10.1097/YIC.0000000000000580","DOIUrl":"10.1097/YIC.0000000000000580","url":null,"abstract":"Psychomotor agitation is a challenging symptom of major depressive disorder with mixed features (MDD-MF), often worsening outcomes and complicating treatment. This retrospective study assessed the efficacy and tolerability of intravenous trazodone in 97 hospitalized patients with MDE-MF. Symptom severity was evaluated using montgomery asberg depression rating Scale (MADRS), young mania rating scale, hamilton anxiety rating scale, GAD-7, and clinical global impression scale-severity of illness (CGI-S) scales, with significant reductions in agitation, anxiety, and irritability observed early during treatment. Correlation analyses revealed significant negative associations between intravenous (IV) trazodone dosage and improvements in MADRS ( r = -0.23; P < 0.05), item 5 of GAD-7 ( r = -0.27; P < 0.001), and CGI-S scores ( r = -0.22; P < 0.05). Therapy duration also correlated negatively with improvements in GAD-7 item 5 ( r = -0.29; P < 0.001) and CGI-S ( r = -0.27; P < 0.001), indicating diminishing returns with prolonged treatment. Regression analyses showed that therapy duration, but not dosage, significantly influenced improvements in GAD-7 item 5 and CGI-S. Trazodone was well-tolerated, with only mild side effects in 11.3% of patients. These findings suggest that IV trazodone effectively reduces agitation and related symptoms in MDD-MF, particularly in the early treatment phase, emphasizing the importance of optimizing treatment duration. Future studies should investigate individualized dosing strategies and explore long-term outcomes in this population.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"367-374"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143004954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Crocus sativus (saffron) adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled trial. 番红花辅助利培酮治疗精神分裂症阴性症状：一项随机、双盲、安慰剂对照试验

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2025-11-01 Epub Date: 2024-12-12 DOI: 10.1097/YIC.0000000000000575

Siamand Mazhar, Ahmad Shamabadi, Kimia Kazemzadeh, Mohammad Aidin Farahvash, Atiye Heidari Dalfard, Bita Fallahpour, Mohammad-Reza Khodaei Ardakani, Shahin Akhondzadeh

{"title":"Crocus sativus (saffron) adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled trial.","authors":"Siamand Mazhar, Ahmad Shamabadi, Kimia Kazemzadeh, Mohammad Aidin Farahvash, Atiye Heidari Dalfard, Bita Fallahpour, Mohammad-Reza Khodaei Ardakani, Shahin Akhondzadeh","doi":"10.1097/YIC.0000000000000575","DOIUrl":"10.1097/YIC.0000000000000575","url":null,"abstract":"Current treatments for schizophrenia encounter resistance, limited efficacy, and limiting complications, necessitating novel approaches. The effects of saffron on negative symptoms were investigated as it has shown neuroprotective and antipsychotic properties. Fifty-six clinically stable chronic schizophrenic outpatients were equally assigned to saffron 15 mg q12hr or placebo groups while continuing risperidone. The Positive and Negative Syndrome Scale (PANSS) was used to assess schizophrenia-related symptoms in weeks 4 and 8. Also, the patients were assessed for the Hamilton depression rating scale (HDRS) and adverse effects. The baseline characteristics of the groups were comparable ( P s > 0.05). There were significant time-treatment interaction effects on negative ( = 0.137), general psychopathology ( = 0.193), and total ( = 0.113) PANSS scores. Affirmatively, their reductions were significantly greater in the saffron group until weeks 4 (Cohen's d s = 0.922, 0.898, and 0.759, respectively) and 8 (Cohen's d s = 0.850, 1.047, and 0.705, respectively). Regarding the negative symptoms, a better 25% response rate was obtained in the saffron group until the endpoint ( P = 0.003). The HDRS scores, extrapyramidal symptom rating scale scores, and side effect frequencies were comparable between the groups ( P s > 0.05). Saffron was beneficial for primary negative symptoms of chronic schizophrenia in a safe and tolerable manner. It also outperformed placebo in improving general psychopathology and total symptoms.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"353-361"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The P300 component of the auditory event-related potential in adult psychiatric and neurologic disorders: a narrative review of clinical and experimental evidence. 听觉事件相关电位的 P300 分量在成人精神和神经疾病中的应用：临床和实验证据综述。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2025-09-01 Epub Date: 2024-08-21 DOI: 10.1097/YIC.0000000000000566

Alberto Raggi, Alessandro Serretti, Raffaele Ferri

{"title":"The P300 component of the auditory event-related potential in adult psychiatric and neurologic disorders: a narrative review of clinical and experimental evidence.","authors":"Alberto Raggi, Alessandro Serretti, Raffaele Ferri","doi":"10.1097/YIC.0000000000000566","DOIUrl":"10.1097/YIC.0000000000000566","url":null,"abstract":"The auditory P300 wave, also known as P3b, is an event-related potential component thought to reflect central information processes involved in stimulus evaluation or categorization. It is typically elicited using the oddball paradigm, which involves mixing low-probability target items with high-probability standard stimuli. Its latency is associated with the timing of cognitive processes such as stimulus evaluation and response preparation, while its amplitude is related to the amount of attentional resources engaged during the task. Despite decades of use in research settings, its application in clinical practice has been limited. Prolongation of latencies and reduction of amplitudes in the auditory P3b have been observed in both psychiatric and neurological conditions. This includes cases where traditional neuropsychological tests are challenging due to severe motor or speech dysfunctions, or in conditions characterized by subtle cognitive deficits. Additionally, specific laterality patterns in psychoses and a loss of P300 habituation in migraines have been described. The wealth of experimental evidence supports the use of this evoked potential, which can be elicited through a relatively simple paradigm, for objectively evaluating cognition in psychiatric and neurological patients, particularly in follow-up assessments. Therefore, the auditory P300 appears to be a valuable tool for monitoring the clinical course of patients with mental and neurological disorders in certain circumstances.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"259-274"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142008697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0